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ABSTRACT
Objective: To analyze the compliance to antiretroviral therapy among HIV/AIDS patients. 
Method: 99 HIV-positive volunteers undergoing treatment responded to a semi-structured 
sociodemographic interview and to a questionnaire that assessed compliance to 
antiretroviral treatment. Results: In the sample analyzed, 52.5% of the volunteers presented 
good/adequate treatment compliance, while 33.3% presented low/insufficient compliance. 
There was no significant difference between men and women in the questionnaire score, 
nor between groups with different levels of education. Conclusion: The main items of the 
questionnaire that contributed to good/adequate compliance were: positive impact of 
treatment on health and quality of life, few side effects after initiation of therapy, and positive 
self-evaluation of participants regarding their compliance to antiretroviral therapy. The main 
barriers detected for compliance to antiretroviral therapy were the lack of knowledge about 
current medications and the lack of information on antiretroviral therapy drugs. 
Descriptors: Antiretroviral Therapy, Highly Active; Immunity; Medication Adherence; 
HIV Infections; Acquired Immunodeficiency Syndrome.
RESUMO
Objetivo: Analisar a adesão de pacientes com HIV/AIDS à terapia antirretroviral. Método: 
99 voluntários portadores do vírus HIV sob tratamento foram submetidos à entrevista social 
e demográfica semiestruturada e ao questionário para avaliação da adesão ao tratamento 
antirretroviral. Resultados: Na amostra analisada, 52,5% dos voluntários apresentaram 
boa/adequada adesão ao tratamento, enquanto 33,3% apresentaram baixa/insuficiente. 
Não houve diferença significativa entre homens e mulheres na pontuação do questionário, 
nem entre os diferentes graus de instrução. Conclusão: Os principais itens do questionário 
que contribuíram para aderência boa/adequada foram o impacto positivo do tratamento 
na saúde e na qualidade de vida, os poucos efeitos colaterais com o início da terapia e a 
autoavaliação positiva dos participantes quanto à própria adesão à terapia antirretroviral. 
As principais barreiras detectadas para a baixa/insuficiente adesão à terapia antirretroviral 
foram o desconhecimento sobre as medicações em uso e o relato de escassez de informação 
sobre os medicamentos da terapia antirretroviral. 
Descritores: Terapia Antirretroviral de Alta Atividade; Imunidade; Adesão à Medicação; 
HIV; Síndrome de Imunodeficiência Adquirida. 
RESUMEN
Objetivo: analizar la adhesión de pacientes con VIH/SIDA a la terapia antirretroviral. 
Método: 99 voluntarios portadores del virus VIH en tratamiento se sometieron a 
entrevista social y demográfica semiestructurada y al cuestionario de evaluación de la 
adhesión al tratamiento antirretroviral. Resultados: en la muestra analizada, el 52,5% 
de los voluntarios presentaba buena/adecuada adhesión al tratamiento, mientras que 
el 33,3%, baja/insuficiente. No había diferencia significativa entre hombres y mujeres 
en la puntuación del cuestionario, ni entre los diferentes grados de instrucción. 
Conclusión: Los puntos principales del cuestionario que contribuyeron a la adherencia 
buena/adecuada fueron: impacto positivo del tratamiento de la salud y la calidad de 
vida, pocos efectos colaterales al principio de la terapia y una autoevaluación positiva de 
los participantes relativa a la propia adhesión a la terapia antirretroviral. Las principales 
barreras detectadas para la baja/insuficiente adhesión a la terapia antirretroviral fueron 
el desconocimiento sobre los remedios en uso y la escasez de información sobre los 
medicamentos de la terapia antirretroviral. 
Descriptores: Terapia Antirretroviral de Alta Actividad; Inmunidad; Adhesión a la 
Medicación; VIH; Síndrome de Inmunodeficiencia Adquirido.
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INTRODUCTION 
Treatment compliance is the acceptance and assimilation of a 
prescribed therapeutic regimen in the daily life of people under-
going treatment, with the crucial participation of the patients in 
the decisions concerning themselves(1). This is a very important 
topic in HIV therapy, since patient and physician establish an al-
liance and the treatment is followed and understood. Therefore, 
treatment compliance will consider patients’ compliance with 
medical prescriptions regarding dosage, number of medications 
per hour, duration of treatment and special recommendations 
for specific medications(2-3).
The human immunodeficiency virus (HIV) is a retrovirus as-
sociated with the progressive immunodeficiency of the person 
infected and loss of CD4+ T lymphocytes and specific globules. 
This compromises the ability of the immune system to defend 
the body, characterizing the disease as chronic and potentially 
lethal(4). A weakened immune system due to low leukocyte count 
and severe lymphopenia makes the patient vulnerable to op-
portunistic diseases, infections and mutations in the processes 
of cell division, leading to conditions, such as lymphomas. Thus, 
increased morbidity and mortality are associated with the con-
sequences of immunodeficiency(5). 
HIV is considered a worldwide epidemic with several associ-
ated risk factors, such as age, gender, ethnicity, sexual orientation 
and average income. In Brazil, 136,945 cases of HIV infection 
were reported from 2007 to June 2016 in the Ministry of Health 
system(6). However, it is believed that a relevant number of indi-
viduals infected by the virus were not identified and, therefore, 
not reported for the regulatory bodies. 
In the 1990s, in order to reduce the effects caused by immu-
nosuppression, antiretroviral therapy (ART) was incorporated 
into HIV treatment, which caused an increase in the quality of life 
and in the life span of the patients. Currently, ART is composed of 
three antiviral drugs with different mechanisms of action, consid-
ering rational use, efficacy, effectiveness, toxicity and dosage(7). 
However, ART can cause a series of metabolic disorders, which 
reduce treatment compliance(8).
Among the adverse effects reported by patients undergoing 
ART or identified by health professionals are: rash, nausea, diarrhea, 
kidney failure, osteopenia, central nervous system adverse events, 
hepatotoxicity, lipoatrophy, hypertriglyceridemia, dyslipidemia 
and insulin resistance(9).
Patient compliance to ART must be clinically and scientifically 
monitored. Clinical monitoring identifies users who do not adhere 
to treatment and scientific monitoring identifies the prevalence 
of noncompliance through statistical analysis(10). In this sense, 
noncompliance to treatment is multicausal, as it may be related 
to the patient’s own understanding, to the side effects of therapy, 
to the information provided by health units or to the inefficiency 
of the social support service(2-3). 
OBJECTIVE




The research followed Resolution no. 466/2012 on Guidelines 
and Norms for Research Involving Human beings. 
The research project was submitted and approved by the 
Research Ethics Committee. 
The Informed Consent Form (ICF) that was read highlighted the 
voluntary participation in the research and the right to withdraw 
at any time and clarified that only the data obtained with scientific 
intention would be used, protecting the privacy of the volunteer.
Design, setting and period
The subjects selected to participate were referred to a pre-de-
termined space in the CSB no. 11 and in the Joint Health Unit of the 
South Wing, a calm environment where the participants signed the 
ICF and then began to respond to the interview and to the instrument. 
The sites selected for the application of the research were 
two basic health units (BHU) with multi-professional teams: the 
Brasília Health Center no. 11 and the Joint Health Unit of the 
South Wing (Day Hospital). Both institutions follow the Ministry 
of Health’s guidelines of the Program on Sexually Transmitted 
Infections, HIV/AIDS and Viral Hepatitis.
Data was collected from April to May 2016.
Population; inclusion and exclusion criteria
The participants of the study were patients on antiretroviral 
treatment and HIV/AIDS followed-up in the health units selected 
for the study.
The inclusion criteria were: being at least 18 years old; positive 
serology for HIV; being on uninterrupted and regular antiretroviral 
therapy for at least six months; being followed up in clinical ap-
pointments scheduled during the period of the research; having 
already been to at least two clinical appointments; being able to 
understand and collaborate by answering the questions. Individuals 
with psychiatric disorders, pregnant women and patients with com-
munication disabilities that prevented them from responding to the 
interview and to the questionnaire were excluded from the study. 
The convenience sample consisted of 99 patients, and the 
majority (n = 70) came from the Brasilia Health Center no. 11, 
only due to their willingness to participate in the study.
Study Protocol
The sociodemographic interview was carried out by the re-
searcher in the health unit, in a private space. Information from 
the last 30 days of therapy was collected. The interview covered 
social, demographic and economic characteristics (age, gender, 
civil status, employment situation, level of education, per capita 
income, acquisition of medicines and sexual orientation). 
In addition, clinical characteristics of each interviewee were as-
sessed: HIV mode of transmission, use of psychiatric medication and 
other medications, social support network, comorbidities, time of 
infection and duration of antiretroviral therapy, number of CD4 + 
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cells per/mm3, viral load, current antiretroviral medication, number of 
pills, dosage, place of residence, alcohol use in the last month, interval 
and time elapsed between the consultations in the referral center.
The semi-structured interview had four subjective questions: 
“How did you feel when you received the diagnosis?”; “What is the 
influence of receiving ART in your life?”; “How do you feel when 
you take the medication?”; “What do you do in your leisure time?”.
The Cuestionario para La Evaluación de La Adhesión al Tratamiento 
Antiretroviral CEAT-VIH online (questionnaire to evaluate compliance 
to antiretroviral treatment – CEAT-VIH) was used in its Brazilian adapted 
and validated by the center specialized in the care of patients infected 
by HIV/AIDS of Porto Alegre, Rio Grande do Sul, where the results 
presented good reliability, high sensitivity and medium specificity(11). 
Participants were invited to participate in the study while waiting 
for their medical consultation. After acceptance, each participant was 
sent to an office in the same place, where, after hearing the objectives 
of the research and reading and signing the ICF, they responded to 
the questionnaires. If the participant had difficulty reading the ques-
tionnaire, it could be presented verbally by the interviewer, without 
influencing the interviewee.
Analysis of results 
The information obtained in the questionnaire was reviewed 
and inserted in a spreadsheet.
Compliance was analyzed using the CEAT-HIV questionnaire 
and its classification in three groups: low/insufficient compliance 
(score ≤74, percentile ≤ 49), good/adequate compliance (score 
between 75 and 79, percentile 50-85) and strict compliance (score 
≥ 80; percentile ≥ 85). The total CEAT-VIH score is the sum of the 
20 items according to the coding assigned to each of the items. 
These scores allow identifying a global rate of compliance to the 
antiretroviral treatment, facilitating the classification of compliance. 
The higher the score obtained, the greater the degree of compli-
ance to treatment.  The minimum score possible was 17 and the 
maximum score 89(11). Continuous data from the questionnaire were 
also used to test hypothesis with social and demographic variables.
The data were expressed in the results and in the tables with mean 
± standard deviation. The data presentation used descriptive statistics. 
The Kolmogorov-Smirnov test was used to verify the normality of the 
data. The relationship between treatment compliance and treatment 
time was analyzed by the Spearman Correlation test. Possible differ-
ences in treatment compliance according to gender were analyzed 
by the Mann-Whitney U test. The relationship between treatment 
compliance and different levels of education was analyzed by the 
Kruskal-Wallis test. When there were significant associations, the 
differences between groups were analyzed by the Mann-Whitney 
U test. All analyzes were performed in the statistical software SPSS 
version 21.0. The level of significance was set at p<0.05.
RESULTS
A total of 99 volunteers (89 men and 10 women) participated 
in the study. Regarding level of education, 39 had only completed 
primary education, 27 had completed secondary education and 
33 had a higher education degree. The treatment time reported 
was of 7.55 ± 5.97 years. 
Treatment compliance was classified according to the CEAT-HIV 
score as low/inadequate (below 52 points), good/adequate (53 
to 78 points) and strict (above 79 points). In the sample analyzed, 
74 volunteers showed good compliance to the treatment, while 
25 volunteers had a strict compliance to treatment, according to 
the responses obtained in the questionnaire (Table 1). 
There was no significant association between treatment com-
pliance and treatment time (p = 0.877; OR = 0.160).  There was no 
significant difference in level of education (p = 0.899) and treatment 
time (p = 0.672) between the groups that presented good/adequate 
and strict compliance. There was also no significant difference in the 
questionnaire score between males and females  (M:75.26 ± 5.53 
vs. F: 76.30 ± 2.54; p = 0,944). There was no difference in the com-
pliance scores between patients with different levels of education 
(Elementary education: 76.51 ± 4.03 vs. Secondary education 72.78 
± 7.15 vs. Higher education: 76.12 ± 4.21; p = 0.066).
The associations between the treatment compliance categories 
(dependent variable), the answers of the questionnaires regarding 
personal characteristics and the CEAT-VIH (independent variable) 
were analyzed for their statistical significance. There were no signifi-
cant associations (p < 0.05) between the frequencies according to 
the treatment compliance classification in 14 of the 20 categories. 
However, significant associations were found in the following 
items: “Do you remember what pills you are currently taking?” (p 
= 0.025), “How much do you think you know about the medica-
tion you take for HIV?” (p = 0.001), “How much do you believe 
your health has improved since you began HIV treatment?” (p = 
0.006), “How do you generally feel about the treatment, since you 
started taking pills?” (p = 0.035), “How do you assess the severity 
of the side effects of the HIV treatment?” (p = 0.000) and “How 
well do you feel you manage taking pills?” (p = 0.010).






Have you ever skipped taking pills?
Always 2 2.0
More than half the time 6 6.1
Approximately half the time 1 1.0
At least once 47 47.5
Never 43 43.4
Have you ever skipped taking pills on account of 
feeling physically better?
Always 2 2.0
More than half the time 0 0.0
Approximately half the time 1 1.0
At least once 11 11.1
Never 85 85.9
Have you ever skipped taking pills on account of 
feeling physically worse after the pills?
Always 2 2.0
More than half the time 0 0.0
Approximately half the time 1 1.0
At least once 9 9.1
Never 87 87.9
To be continued
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Have you ever skipped taking pills on account of 
feeling sad or depressed?
Always 1 1.0
More than half the time 0 0.0
Approximately half the time 0 0.0
At least once 3 3.0
Never 95 96.0
Do you remember what pills you are currently taking?
No 48 48.5
Yes 51 51.5
How would you rate your relationship with your 
doctor?
Very bad 0 0.0
Somewhat bad 1 1.0
Regular 3 3.0
Could improve 8 8.1
Good 87 87.9
How hard do you try to keep up with treatment?
Not at all 1 1.0




How much do you think you know about the 
medication you take for HIV?
Nothing 15 15.2
A little bit 16 16.2
Some things 19 19.2
Quite a bit 17 17.2
A lot 32 32.3
How much do you think taking pills helps you?
Not at all 3 3.0
A little 2 2.0
Somewhat 3 3.0
Quite a lot 18 18.2
Very much 73 73.7
How much do you believe your health has 
improved since you began HIV treatment?
Not at all 4 4.0
A little 0 0.0
Somewhat 8 8.1
Quite a lot 16 16.2
Very much 71 71.7
To what extent do you think you are able to 
proceed with treatment?
Not at all 0 0.0




Do you usually take your pills at the correct time?
No, never 1 1.0
Yes, sometimes 5 5.1
Yes, approximately half the time 6 6.1
Yes, many times 15 15.2
Yes, always 72 72.7
When the results of the tests are good, does your 
doctor use them to give you  motivation to follow the 
treatment?
No, never 4 4.0






Yes, approximately half the time 1 1.0
Yes, many times 11 11.1
Yes, always 79 79.8
How do you generally feel about the treatment, since 
you started taking pills?




Very satisfied 54 54.5
How do you assess the severity of the side effects 
of the HIV treatment?
Very severe 13 13.1
Severe 3 3.0
Moderately severe 12 12.1
A little severe 20 20.2
Not severe 51 51.5
How much time do you think you lose to manage 
taking pills?
A lot of time 1 1.0
Quite a lot time 1 1.0
Some time 1 1.0
A little time 10 10.1
No time at all 86 86.9
How well do you feel you manage taking pills?
I’m not compliant 0 0.0
I’m a little compliant 2 2.0
I’m compliant 5 5.1
I’m very compliant 17 17.2
I’m totally compliant 75 75.8
How difficult it is for you to take pills?
Very difficult 1 1.0
Really difficult 1 1.0
Neutral 0 0.0
Easy 10 10.1
Very easy 87 87.9
Since you are being treated, have you ever stopped 
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n = 14 pa
F % F % F % F %
Have you ever skipped taking pills? 0.098
Always 2 2.0 2 6.0 0 0.0 0 0.0
More than half the time 6 6.0 4 12.1 2 3.8 0 0.0
Approximately half the time 1 1.0 1 3.0 0 0.0 0 0.0
At least once 47 47.4 17 51.5 25 48.0 5 35.7
Never 43 43.4 9 27.2 25 48.0 9 64.2
Have you ever skipped taking pills on account of feeling physically better? 0.114
Always 2 2.0 2 6.0 0 0.0 0 0.0
More than half the time 0 0.0 0 0.0 0 0.0 0 0.0
Approximately half the time 1 1.0 1 3.0 0 0.0 0 0.0
At least once 11 11.1 6 18.1 5 9.6 0 0.0
Never 85 85.8 24 72.7 47 90.3 14 100.0
Have you ever skipped taking pills on account of feeling physically 
worse after the pills? 0.057
Always 2 2.0 2 6.0 0 0.0 0 0.0
More than half the time 0 0.0 0 0.0 0 0.0 0 0.0
Approximately half the time 1 1.0 1 3.0 0 0.0 0 0.0
At least once 9 9.0 6 18.1 3 5.7 0 0.0
Never 87 87.8 24 72.7 49 94.2 14 100.0
Have you ever skipped taking pills on account of feeling sad or depressed? 0.438
Always 1 1.0 1 3.0 0 0.0 0 0.0
More than half the time 0 0.0 0 0.0 0 0.0 0 0.0
Approximately half the time 0 0.0 0 0.0 0 0.0 0 0.0
At least once 3 3.0 2 6.0 1 1.9 0 0.0
Never 95 95.9 30 90.9 51 98.0 14 100.0
Do you remember what pills you are currently taking? 0.025
No 48 48.4 22 66.6 22 42.3 4 28.5
Yes 51 51.5 11 33.3 30 57.6 10 71.4
How would you rate your relationship with your doctor? 0.502
Very bad 0 0.0 0 0.0 0 0.0 0 0.0
Somewhat bad 1 1.0 1 3.0 0 0.0 0 0.0
Regular 3 3.0 2 6.0 1 1.9 0 0.0
Could improve 8 8.0 3 9.0 5 9.6 0 0.0
Good 87 87.8 27 81.8 46 88.4 14 100.0
How hard do you try to keep up with treatment? 0.086
Not at all 1 1.0 1 3.0 0 0.0 0 0
A little 0 0.0 0 0.0 0 0.0 0 0.0
Somewhat 4 4.0 4 12.1 0 0.0 0 0.0
Quite 26 26.2 9 27.2 14 26.9 3 21.4
Very 68 68.6 19 57.5 38 73.0 11 78.5
How much do you think you know about the medication you take for HIV? 0.001
Nothing 15 15.1 9 27.2 6 11.5 0 0
A little bit 16 16.1 8 24.2 8 15.3 0 0.0
Some things 19 19.1 6 18.1 13 25.0 0 0.0
Quite a bit 17 17.1 2 6.0 12 23.0 3 21.4
A lot 32 32.3 8 24.2 13 25.0 11 78.5
How much do you think taking pills helps you? 0.068
Not at all 3 3.0 3 9.0 0 0.0 0 0.0
A little 2 2.0 2 6.0 0 0.0 0 0.0
Somewhat 3 3.0 2 6.0 1 1.9 0 0.0
Quite a lot 18 18.1 5 15.1 12 23.0 1 7.1
Very much 73 73.7 21 63.6 39 75.0 13 92.8
How much do you believe your health has improved since you began 
HIV treatment? 0.006
Not at all 4 4.0 4 12.1 0 0.0 0 0.0
A little 0 0.0 0 0.0 0 0.0 0 0.0
Somewhat 8 8.0 5 15.1 3 5.7 0 0.0
Quite a lot 16 16.1 7 21.2 9 17.3 0 0.0
Very much 71 71.7 17 51.5 40 76.9 14 100.0
To be continued
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n = 14 pa
F % F % F % F %
To what extent do you think you are able to proceed with treatment? 0.473
Not at all 0 0.0 0 0.0 0 0.0 0 0.0
A little 0 0.0 0 0.0 0 0.0 0 0.0
Somewhat 3 3.0 2 6.0 1 1.9 0 0.0
Quite a lot 9 9.0 3 9.0 6 11.5 0 0.0
Very much 87 87.8 28 84.8 45 86.5 14 100.0
Do you usually take your pills at the correct time? 0.093
No, never 1 1.0 1 3.0 0 0.0 0 0.0
Yes, sometimes 5 5.0 4 12.1 1 1.9 0 0.0
Yes, approximately half the time 6 6.0 4 12.1 2 3.8 0 0.0
Yes, many times 15 15.1 6 18.1 8 15.3 1 7.1
Yes, always 72 72.7 18 54.5 41 78.8 13 92.8
When the results of the tests are good, does your doctor use them to give 
you  motivation to follow the treatment? 0.521
No, never 4 4.0 3 9.0 1 1.9 0 0.0
Yes, sometimes 4 4.0 2 6.0 2 3.8 0 0.0
Yes, approximately half the time 1 1.0 1 3.0 0 0.0 0 0.0
Yes, many times 11 11.1 4 12.1 6 11.5 1 7.1
Yes, always 79 79.7 23 69.6 43 82.6 13 92.8
How do you generally feel about the treatment, since you started 
taking pills? 0.035
Very dissatisfied 0 0.0 0 0.0 0 0.0 0 0.0
Dissatisfied 4 4.0 2 6.0 2 3.8 0 0.0
Neutral 6 6.0 4 12.1 2 3.8 0 0.0
Satisfied 35 35.3 17 51.5 13 25.0 5 35.7
Very satisfied 54 54.5 10 30.3 35 67.3 9 64.2
How do you assess the severity of the side effects of the HIV 
treatment? 0.000
Very severe 13 13.1 12 36.3 1 1.9 0 0.0
Severe 3 3.0 0 0.0 3 5.7 0 0.0
Moderately severe 12 12.1 6 18.1 6 11.5 0 0.0
A little severe 20 20.2 4 12.1 12 23.0 4 28.5
Not severe 51 51.5 11 33.3 30 57.6 10 71.4
How much time do you think you lose to manage taking pills? 0.231
A lot of time 1 1.0 1 3.0 0 0.0 0 0.0
Quite a lot time 1 1.0 0 0.0 0 0.0 1 7.1
Some time 1 1.0 1 3.0 0 0.0 0 0.0
A little time 10 10.1 4 12.1 5 9.6 1 7.1
No time at all 86 86.8 27 81.8 47 90.3 12 85.7
How well do you feel you manage taking pills? 0.010
I’m not compliant 0 0.0 0 0.0 0 0.0 0 0.0
I’m a little compliant 2 2.0 2 6.0 0 0.0 0 0.0
I’m compliant 5 5.0 4 12.1 1 1.9 0 0.0
I’m very compliant 17 17.1 9 27.2 8 15.3 0 0.0
I’m totally compliant 75 75.7 18 54.5 43 82.6 14 100.0
How difficult it is for you to take pills? 0.612
Very difficult 1 1.0 1 3.0 0 0.0 0 0.0
Really difficult 1 1.0 1 3.0 0 0.0 0 0.0
Neutral 0 0.0 0 0.0 0 0.0 0 0.0
Easy 0 10.1 4 12.1 5 9.6 1 7.1
Very easy 87 87.8 27 81.8 47 90.3 13 92.8
Since you are being treated, have you ever stopped taking your 
medication one full day, or more than one? 0.155
0 33 33.3 7 21.2 18 34.6 8 57.1
1 19 19.1 4 12.1 12 23.0 3 21.4
2 7 7.0 1 3.0 6 11.5 0 0.0
3 5 5.0 2 6.0 1 1.9 2 14.2
5 4 4.0 1 3.0 3 5.7 0 0.0
7 5 5.0 3 9.0 2 3.8 0 0.0
11 1 1.0 0 0.0 0 0.0 1 7.1
14 1 1.0 1 3.0 0 0.0 0 0.0
Table 2 (concluded)
To be continued
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n = 14 pa
F % F % F % F %
15 1 1.0 0 0.0 1 1.9 0 0.0
24 1 1.0 1 3.0 0 0.0 0 0.0
30 4 4.0 2 6.0 2 3.8 0 0.0
45 1 1.0 1 3.0 0 0.0 0 0.0
60 3 3.0 3 9.0 0 0.0 0 0.0
72 1 1.0 0 0.0 1 1.9 0 0.0
90 1 1.0 1 3.0 0 0.0 0 0.0
120 4 4.0 2 6.0 2 3.8 0 0.0
180 2 2.0 2 6.0 0 0.0 0 0.0
365 3 3.0 1 3.0 2 3.8 0 0.0
730 2 2.0 0 0.0 2 3.8 0 0.0
1095 1 1.0 1 3.0 0 0.0 0 0.0
Do you have specific strategies to remember taking pills? 0.913
No 66 66.6 22 66.6 34 65.3 10 71.4
Yes 33 33.3 11 33.3 18 34.6 4 28.5
Table 2 (concluded)
DISCUSSION
The main results of the study show a good/adequate treatment 
compliance (74.7% of the volunteers) and strict compliance (26.2% 
of the volunteers), which did not seem to change along with level 
of education, treatment time and gender. The items “Do you re-
member what pills you are currently taking?”; “How much do you 
think you know about the medication you take for HIV?”; “How 
much do you believe your health has improved since you began 
HIV treatment?”; “How do you generally feel about the treatment, 
since you started taking pills?”; “How do you assess the severity of 
the side effects of the HIV treatment?”; and “How well do you feel 
you manage taking pills?” represent key issues for ART compliance.
Compliance to antiretroviral therapy among HIV patients is 
extremely important because this treatment can improve quality 
of life, reduce morbidities and increase survival(3). However, com-
pliance is one of the greatest challenges of the multi-professional 
team involved in the treatment, since it can be influenced by factors 
related to the physical, physiological and psychological changes 
brought by the disease and by the treatment. In addition, treat-
ment compliance is also influenced by the patients’ personalities, 
their involvement and empathy with the multi-professional health 
team, and their social interactions(3,12). In the present study, the re-
lationship between patients and their physicians was evaluated as 
good by more than 87% of the interviewees, and the involvement 
with their own treatment – analyzed through questions such as 
the patient’s effort to follow the treatment – was high, which can 
be interpreted as positive aspects for compliance to ART. 
Likewise, treatment compliance seems to be determined 
by a number of factors such as morbidities, number of pills per 
day, chronic and infectious conditions, environmental factors, 
structural and personal factors, educational level and income(13-14). 
According to Silva et al.(3), a higher level of education can be 
related to a better understanding of the pathology and of the 
drug therapy, contributing to a greater compliance to treat-
ment, which was also observed in the study by Myiada et al.(14). 
On the other hand, a low level of education has been related to 
a change in the profile of the patient, presenting an association 
not only with treatment compliance but also with virus infection 
itself(3,15). However, in the present study there was no statistical 
difference between groups with different levels of education in 
their treatment compliance score. 
Regarding gender, Auld et al.(16), Lemos et al.(17) e May et al.(18) 
found a predominance of men in groups with low compliance to 
treatment, negative prognosis and unsatisfactory clinical results, 
including their relations with the multi-professional health team. 
In the work of Betancur et al.(19), there was a significantly higher 
proportion of women among non-adherent patients. However, 
in the present study, there was no difference between men and 
women in compliance to antiretroviral treatment. Ioannides et al.(20) 
also did not find differences between genders when comparing 
154 adolescent males with 134 adolescent females. In this sense, 
it is possible that environmental, psychological and physical 
factors are more relevant to treatment compliance than gender.
In addition, compliance to HIV treatment does not appear to 
vary between adolescents and adults. However, an individual-
ized and multidisciplinary follow-up care must be performed by 
the health team, which should provide care specifically directed 
to the target public, with compliance programs composed of 
psychological interventions that can meet the informational, 
developmental and fundamental needs of each age group(21).
The antiretroviral therapy can lead to a range of metabolic 
disorders: despite increasing quality of life and patient survival, 
ART can be associated with, among other consequences, lipo-
dystrophy, which is a metabolic complication of fat loss, fat gain, 
or a combination of fat loss and gain(8). This syndrome can cause 
fat loss in peripheral regions such as face, buttocks, arms, legs; 
central fat accumulation in the abdomen, breasts and dorsocervi-
cal region; or an association between the two forms described(22). 
According to Finkelstein et al.(8) the abnormal fat distribution 
has a profound negative physical and emotional impact, so it 
should be considered as an important aspect to be observed in 
the clinical management of patients undergoing ART. 
In addition, compliance to ART is influenced by the presence 
of co-infections and the amount of drugs required to treat them. 
According to Lemos et al.(17), patients co-infected with Tuberculosis 
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(HIV/TB) tend to present lower compliance to treatment, especially 
low income men, who have three or more clinical conditions and 
who have a partner who is also infected. However, the results of 
the study mentioned above demonstrated a negative relation-
ship between treatment time and treatment compliance, which 
was not confirmed by the present study. 
Sagarduy et al.(23) argue that factors of the patient’s personality, 
such as decision-making and tolerance of frustration, are directly 
related to compliance to antiretroviral therapy. For Betencur et al.(19), 
psychoeducation can be used to address negative beliefs regarding 
treatment and to screen for symptoms of anxiety and depression. 
Chenneville et al.(24) point out some fundamental determinants for 
compliance to antiretroviral treatment among patients infected 
with HIV: an intervention capable of remembering patients, mainly 
younger ones, to take their medication; physical, cognitive, affective 
and/or environmental factors as facilitators or barriers to treatment 
compliance; the appropriate inclusion of a multi-professional health 
team; and providing enough information to encourage compliance. 
In addition, there is a strong association between the presence of 
moderate or severe levels of anxiety, symptoms of depression and 
low scores on quality of life scales, and low compliance to ART(19). 
Limitations of the study
The analysis referring to questionnaires undoubtedly involves 
the individuality of the answers, which directly influences the 
evaluation of the score, since the subjects must look back on their 
own experience with the treatment to answer the questionnaire.
Contributions to the  nursing, health or public policy fields
It is imperative to understand how the patients perceive 
themselves during the process of illness and treatment so that an 
individualized approach can be provided. In addition, the discus-
sion about the factors that influence compliance to treatment 
with antiretroviral drugs is common among health professionals. 
In this sense, reinforcing the impressions with the evaluation of 
objective questionnaires contributes to the understanding of 
the patients’ point of view about their own care. 
CONCLUSION
In the present study, compliance to antiretroviral treatment 
among patients with the HIV virus was predominantly good/
adequate. The main items of the CEAT-VIH questionnaire that 
contributed to this conclusion were the positive impact of the 
treatment on health and quality of life, few side effects after initia-
tion of therapy and the positive self-evaluation of the participants 
regarding their compliance to ART. 
The main barriers detected for compliance to ART were the 
lack of knowledge about current medications and having little or 
no information about the drugs. Therefore, adequate information 
and patient awareness should be a priority in ART care services. 
Finally, the importance of the relationship between patient and 
professional is reinforced, and the professional must also inform, 
explain and solve doubts to stimulate adequate compliance to 
antiretroviral therapy.
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